Fingerprint
Dive into the research topics where Michaella Bhira Goldstein Schwarz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
YOSEMITE and RHINE Investigators, Jun 2024, In: Ophthalmology. 131, 6, p. 708-723 16 p.Research output: Contribution to journal › Article › peer-review
Open Access103 Scopus citations -
POLYPOIDAL LESIONS ASSOCIATED with CHOROIDAL NEVI
Gomel, N., Goldstein, M., Fung, A. T., Iovino, C., Tatti, F., Peiretti, E., Habot-Wilner, Z., Loewenstein, A., Iglicki, M. & Zur, D., 1 Jan 2024, In: Retina. 44, 1, p. 136-143 8 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Reply
Gomel, N., Goldstein, M., Fung, A. T., Iovino, C., Tatti, F., Peiretti, E., Habot-Wilner, Z., Loewenstein, A., Iglicki, M. & Zur, D., 1 Jul 2024, In: Retina. 44, 7, p. e47-e48Research output: Contribution to journal › Letter › peer-review
-
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
TENAYA and LUCERNE Investigators, Aug 2024, In: Ophthalmology. 131, 8, p. 914-926 13 p.Research output: Contribution to journal › Article › peer-review
Open Access133 Scopus citations -
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration
Opthea Study Group Investigators, Jun 2023, In: Ophthalmology. 130, 6, p. 588-597 10 p.Research output: Contribution to journal › Article › peer-review
Open Access51 Scopus citations